FBLG
FibroBiologics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$1.77
+0.57%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 234.0K | 832.0K | — | — | — |
| Gross Profit | (234.0K) | (832.0K) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 8.2M | 7.4M | 4.5M | 2.4M | 1.1M |
| SG&A Expense | 8.5M | 9.2M | 9.2M | 6.5M | 3.3M |
| General & Admin Expense | 8.5M | 9.2M | 9.2M | 6.5M | 3.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (234.0K) | (832.0K) | — | — | — |
| Total Operating Expenses | 16.5M | 15.8M | 13.7M | 8.9M | 4.5M |
| Cost and Expenses | 16.7M | 16.6M | 13.7M | 8.9M | 4.5M |
| Operating Income (EBIT) | (16.7M) | (16.6M) | (13.7M) | (8.9M) | (4.5M) |
| Non-Operating | |||||
| Interest Income | 133.0K | 247.0K | 251.0K | — | — |
| Interest Expense | 215.0K | 204.0K | 20.0K | 147.0K | 654.0K |
| Net Interest Income | (82.0K) | 43.0K | 231.0K | (147.0K) | (654.0K) |
| Other Non-Op Income/Expense | (1.4M) | (2.0M) | 2.6M | (7.6M) | (654.0K) |
| Non-Operating Income (excl Interest) | 1.1M | 1.8M | (2.6M) | 7.4M | — |
| EBT (Pre-Tax Income) | (18.1M) | (18.6M) | (11.2M) | (16.5M) | (5.1M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (18.1M) | (18.6M) | (11.2M) | (16.5M) | (5.1M) |
| Earnings from Cont. Ops | (18.1M) | (18.6M) | (11.2M) | (16.5M) | (5.1M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (18.1M) | (18.6M) | (11.2M) | (19.1M) | (5.1M) |
| Per Share | |||||
| Basic EPS | ($6.00) | ($8.35) | ($6.80) | ($11.80) | ($3.20) |
| Diluted EPS | ($6.00) | ($8.35) | ($6.80) | ($11.80) | ($3.20) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 3.8M | 2.2M | 1.6M | 1.6M | 1.6M |
| Diluted Shares Outstanding | 3.8M | 2.2M | 1.6M | 1.6M | 1.6M |
| Profitability Metrics | |||||
| EBITDA | (17.1M) | (17.6M) | (10.6M) | (15.9M) | (4.4M) |
| D&A | 702.0K | 832.0K | 573.0K | 437.0K | 94.0K |
| EBIT | (17.8M) | (18.4M) | (11.1M) | (16.3M) | (4.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026